Healthcare Industry ITP Therapeutics Market Size 2020

Your Catalyst To a Lucrative Business
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics
Market Size, Regional Outlook, Industry Overview and Forecasts
to 2020
"The Idiopathic Thrombocytopenic Purpura (ITP)
Therapeutics market is driven by favorable
government policies such as the U.S. Orphan Drug
Act. Demand of combination therapies like
dexamethasone and TPO-RA is another factor which
may influence market growth."
The worldwide Idiopathic Thrombocytopenic Purpura Therapeutics Market is projected to attain nearly USD
566 million by 2020. It can expand at a 5.9 % CAGR over the forecast period (2014-2020). The market stood at
around USD 382 million in 2013. It is driven by favorable government policies such as the U.S. Orphan Drug Act.
Demand of combination therapies like dexamethasone and TPO-RA is another factor which may influence
market growth.
ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to
excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia
and can affect children and adults alike. ITP affects nearly 0.3% out of every 100,000 in the U.S.
Commercialization of new drugs like IVIG3I 10% and Avatrombopag is anticipated to propel demand over the
forecast period.
Browse Details of Report @ https://www.hexaresearch.com/research-report/idiopathic-thrombocytopenic-
purpura-itp-therapeutics-industry
Follow Us: